Prognostic influence of hepatic margin after resection of colorectal liver metastasis: role of modern preoperative chemotherapy
- 311 Downloads
Modern chemotherapy (CTX) increases survival in stage IV colorectal cancer. In colorectal liver metastases (CLM), neoadjuvant (neo) CTX may increase resectability and improve survival. Due to widespread use of CTX in CLM, recent studies assessed the role of the hepatic margin after CTX, with conflicting results. We evaluated the outcome after resection of CLM in relation to CTX and hepatic resection status.
Since 2000, 334 patients with first hepatic resection for isolated CLM were analyzed. Thirty-two percent had neoadjuvant chemotherapy (targeted therapy in 42%). Sixty-eight percent never had CTX before hepatectomy or longer than 6 months before resection. The results were gained by analysis of our prospective database.
Positive hepatic margins occurred in 8% (independent of neoCTx). Patients after neoCTX had higher numbers of CLM (p < 0.01) and a longer duration of surgery (p < 0.03). After hepatectomy, 5-year survival was 45% and correlated strongly with the margin status (47% in R-0 and 21% in R-1; p < 0.001). Survival also correlated with margin status in the subgroups with neoCTX (p < 0.01) or without neoCTx (p < 0.01). In multivariate analysis of the entire group, hepatic margin status (RR 3.2; p < 0.001) and age > 65 years (RR 1.6; p < 0.01) were associated with poorer survival. In the subgroup of patients after neoCTX (n = 106), only the resection margin was an independent predictor of survival (p < 0.001).
In patients with isolated colorectal liver metastases undergoing resection, the hepatic margin status was the strongest independent prognostic factor. This effect was also present after neoadjuvant chemotherapy for CLM.
KeywordsColorectal liver metastasis Neoadjuvant chemotherapy Hepatic resection Resection margin Survival
This manuscript is dedicated to Professor Ulrich T. Hopt, Head of the Department of Surgery of the University of Freiburg, who retired in 2016 after more than 40 years in Academic Surgery.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.House MG, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP, Brennan MF, Blumgart LH, Jarnagin WR, D'Angelica MI (2010) Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 210:744–752. https://doi.org/10.1016/j.jamcollsurg.2009.12.040 CrossRefPubMedGoogle Scholar
- 2.Viganò L, Russolillo N, Ferrero A, Langella S, Sperti E, Capussotti L (2012) Evolution of long-term outcome of liver resection for colorectal metastases: analysis of actual 5-year survival rates over two decades. Ann Surg Oncol 19:2035–2044. https://doi.org/10.1245/s10434-011-2186-1 CrossRefPubMedGoogle Scholar
- 3.Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T, Fédération Francophone de Cancérologie Digestive (FFCD) (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215. https://doi.org/10.1016/S1470-2045(13)70447-9 CrossRefPubMedGoogle Scholar
- 4.Bonney GK, Coldham C, Adam R, Kaiser G, Barroso E, Capussotti L, Laurent C, Verhoef C, Nuzzo G, Elias D, Lapointe R, Hubert C, Lopez-Ben S, Krawczyk M, Mirza DF, LiverMetSurvey International Registry Working Group (2015) Role of neoadjuvant chemotherapy in resectable synchronous colorectal liver metastasis; an international multi-center data analysis using LiverMetSurvey. J Surg Oncol 111:716–724. https://doi.org/10.1002/jso.23899 CrossRefPubMedGoogle Scholar
- 6.Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH (2014) Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 25:1018–1025. https://doi.org/10.1093/annonc/mdu088 CrossRefPubMedGoogle Scholar
- 7.Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715–722. https://doi.org/10.1097/01.sla.0000160703.75808.7d CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Tabernero J, Teh C, Van Cutsem E, Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group (2012) The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17:1225–1239. https://doi.org/10.1634/theoncologist.2012-0121 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Andreou A, Aloia TA, Brouquet A, Dickson PV, Zimmitti G, Maru DM, Kopetz S, Loyer EM, Curley SA, Abdalla EK, Vauthey JN (2013) Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 257:1079–1088. https://doi.org/10.1097/SLA.0b013e318283a4d1 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Sadot E, Groot Koerkamp B, Leal JN, Shia J, Gonen M, Allen PJ, DeMatteo RP, Kingham TP, Kemeny N, Blumgart LH, Jarnagin WR, DʼAngelica MI (2015) Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? Ann Surg 262:476–485. https://doi.org/10.1097/SLA.0000000000001427 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Ayez N, Lalmahomed ZS, Eggermont AM, Ijzermans JN, de Jonge J, van Montfort K, Verhoef C (2012) Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann Surg Oncol 19:1618–1627. https://doi.org/10.1245/s10434-011-2114-4 CrossRefPubMedGoogle Scholar
- 16.Hosokawa I, Allard MA, Gelli M, Ciacio O, Vibert E, Cherqui D, Sa Cunha A, Castaing D, Miyazaki M, Adam R (2016) Long-term survival benefit and potential for cure after R1 resection for colorectal liver metastases. Ann Surg Oncol 23:1897–1905. https://doi.org/10.1245/s10434-015-5060-8 CrossRefPubMedGoogle Scholar
- 18.Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, Sartoretti P, Dousset B, Majno PE, Soubrane O, Chaussade S, Mentha G, Terris B (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299–304. https://doi.org/10.1093/annonc/mdl386 CrossRefPubMedGoogle Scholar
- 19.Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306–1315. https://doi.org/10.1016/S1470-2045(15)00122-9 CrossRefPubMedGoogle Scholar
- 21.Cady B, Jenkins RL, Steele GD, Lewis WD, Stone MD, McDermott WV, Jessup JM, Bothe A, Lalor P, Lovett EJ, Lavin P, Linehan DC (1998) Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 227:566–571CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Shirabe K, Takenaka K, Gion T, Fujiwara Y, Shimada M, Yanaga K, Maeda T, Kajiyama K, Sugimachi K (1997) Analysis of prognostic risk factors in hepatic resection for metastatic colorectal carcinoma with special reference to the surgical margin. Br J Surg 84:1077–1080. https://doi.org/10.1046/j.1365-2168.1997.02743.x CrossRefPubMedGoogle Scholar
- 25.Viganò L, Procopio F, Cimino MM, Donadon M, Gatti A, Costa G, Del Fabbro D, Torzilli G (2016) Is tumor detachment from vascular structures equivalent to R0 resection in surgery for colorectal liver metastases? An observational cohort. Ann Surg Oncol 23:1352–1360. https://doi.org/10.1245/s10434-015-5009-y CrossRefPubMedGoogle Scholar